- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Volume 2011 (2011), Article ID 274629, 7 pages
Friend Turns Foe: Transformation of Anti-Inflammatory HDL to Proinflammatory HDL during Acute-Phase Response
1Tata Proteomics and Coagulation Unit, Thrombosis Research Institute, Bangalore, India
2Narayana Hrudayalaya Hospital, Bangalore, India
3Thrombosis Research Institute, London, UK
Received 31 August 2010; Accepted 1 November 2010
Academic Editor: Jeffrey Cohn
Copyright © 2011 Hima Bindu G et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- D. J. Gordon and B. M. Rifkind, “High-density lipoprotein–the clinical implications of recent studies,” New England Journal of Medicine, vol. 321, no. 19, pp. 1311–1316, 1989.
- P. W. F. Wilson, R. D. Abbott, and W. P. Castelli, “High density lipoprotein cholesterol and mortality. The Framingham heart study,” Arteriosclerosis, vol. 8, no. 6, pp. 737–741, 1988.
- P. Barter, J. Kastelein, A. Nunn et al., “High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions,” Atherosclerosis, vol. 168, no. 2, pp. 195–211, 2003.
- B. F. Asztalos and E. J. Schaefer, “HDL in atherosclerosis: actor or bystander?” Atherosclerosis, vol. 4, no. 1, pp. 21–29, 2003.
- A. Kontush and M. J. Chapman, “Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis,” Pharmacological Reviews, vol. 58, no. 3, pp. 342–374, 2006.
- K. Sattler and B. Levkau, “Sphingosine-1-phosphate as a mediator of high-density lipoprotein effects in cardiovascular protection,” Cardiovascular Research, vol. 82, no. 2, pp. 201–211, 2009.
- G. Assmann and A. M. Gotto, “HDL cholesterol and protective factors in atherosclerosis,” Circulation, vol. 109, no. 23, supplement 1, pp. 8–14, 2004.
- G. F. Lewis and D. J. Rader, “New insights into the regulation of HDL metabolism and reverse cholesterol transport,” Circulation Research, vol. 96, no. 12, pp. 1221–1232, 2005.
- W. Le Goff, M. Guerin, and M. J. Chapman, “Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia,” Pharmacology and Therapeutics, vol. 101, no. 1, pp. 17–38, 2004.
- P. J. Barter, H. B. Brewer, M. J. Chapman, C. H. Hennekens, D. J. Rader, and A. R. Tall, “Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 2, pp. 160–167, 2003.
- M. Navab, S. S. Imes, S. Y. Hama et al., “Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein,” Journal of Clinical Investigation, vol. 88, no. 6, pp. 2039–2046, 1991.
- M. Navab, J. A. Berliner, G. Subbanagounder et al., “HDL and the inflammatory response induced by LDL-derived oxidized phospholipids,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 21, no. 4, pp. 481–488, 2001.
- G. K. Marathe, G. A. Zimmerman, and T. M. McIntyre, “Platelet-activating factor acetylhydrolase, and not paraoxonase-1, is the oxidized phospholipid hydrolase of high density lipoprotein particles,” Journal of Biological Chemistry, vol. 278, no. 6, pp. 3937–3947, 2003.
- A. M. Fogelman, “When good cholesterol goes bad,” Nature Medicine, vol. 10, no. 9, pp. 902–903, 2004.
- P. W. Baker, K. A. Rye, J. R. Gamble, M. A. Vadas, and P. J. Barter, “Ability of reconstituted high density lipoproteins to inhibit cytokine-induced expression of vascular cell adhesion molecule-1 in human umbilical vein endothelial cells,” Journal of Lipid Research, vol. 40, no. 2, pp. 345–353, 1999.
- D. Recalde, M. A. Ostos, E. Badell et al., “Human apolipoprotein A-IV reduces secretion of proinflammatory cytokines and atherosclerotic effects of a chronic infection mimicked by lipopolysaccharide,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 4, pp. 756–761, 2004.
- M. D. Saemann, M. Poglitsch, C. Kopecky, M. Haidinger, W. H. Horl, and T. Weichhart, “The versatility of HDL: a crucial anti-inflammatory regulator,” European Journal of Clinical Investigation. In press.
- P. J. Barter, P. W. Baker, and K. A. Rye, “Effect of high-density lipoproteins on the expression of adhesion molecules in endothelial cells,” Current Opinion in Lipidology, vol. 13, no. 3, pp. 285–288, 2002.
- B. J. Van Lenten, S. Y. Hama, F. C. De Beer et al., “Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures,” Journal of Clinical Investigation, vol. 96, no. 6, pp. 2758–2767, 1995.
- M. Navab, S. T. Reddy, B. J. Van Lenten, G. M. Anantharamaiah, and A. M. Fogelman, “The role of dysfunctional HDL in atherosclerosis,” Journal of Lipid Research, vol. 50, supplement, pp. S145–S149, 2009.
- B. J. Ansell, G. C. Fonarow, and A. M. Fogelman, “The paradox of dysfunctional high-density lipoprotein,” Current Opinion in Lipidology, vol. 18, no. 4, pp. 427–434, 2007.
- B. F. Asztalos, M. De La Llera-Moya, G. E. Dallal, K. V. Horvath, E. J. Schaefer, and G. H. Rothblat, “Differential effects of HDL subpopulations on cellular ABCA1- and SR-BI-mediated cholesterol efflux,” Journal of Lipid Research, vol. 46, no. 10, pp. 2246–2253, 2005.
- C. R. Wooton-Kee, B. B. Boyanovsky, M. S. Nasser, W. J. S. De Villiers, and N. R. Webb, “Group V sPLA2 hydrolysis of low-density lipoprotein results in spontaneous particle aggregation and promotes macrophage foam cell formation,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 4, pp. 762–767, 2004.
- B. J. Van Lenten, A. C. Wagner, D. P. Nayak, S. Hama, M. Navab, and A. M. Fogelman, “High-density lipoprotein loses its anti-inflammatory properties during acute influenza A infection,” Circulation, vol. 103, no. 18, pp. 2283–2288, 2001.
- W. Khovidhunkit, R. A. Memon, K. R. Feingold, and C. Grunfeld, “Infection and inflammation-induced proatherogenic changes of lipoproteins,” Journal of Infectious Diseases, vol. 181, no. 6, pp. S462–S472, 2000.
- W. Khovidhunkit, M. S. Kim, R. A. Memon et al., “Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host,” Journal of Lipid Research, vol. 45, no. 7, pp. 1169–1196, 2004.
- E. Esteve, W. Ricart, and J. M. Fernández-Real, “Dyslipidemia and inflammation: an evolutionary conserved mechanism,” Clinical Nutrition, vol. 24, no. 1, pp. 16–31, 2005.
- A. Urundhati, Y. Huang, J. A. Lupica, J. D. Smith, J. A. DiDonato, and S. L. Hazen, “Modification of high density lipoprotein by myeloperoxidase generates a pro-inflammatory particle,” Journal of Biological Chemistry, vol. 284, no. 45, pp. 30825–30835, 2009.
- V. G. Cabana, J. R. Lukens, K. S. Rice, T. J. Hawkins, and G. S. Getz, “HDL content and composition in acute phase response in three species: triglyceride enrichment of HDL a factor in its decrease,” Journal of Lipid Research, vol. 37, no. 12, pp. 2662–2674, 1996.
- E. J. Schaefer, J. R. McNamara, B. F. Asztalos et al., “Effects of atorvastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein-associated phospholipase A in patients with coronary heart disease versus control subjects,” American Journal of Cardiology, vol. 95, no. 9, pp. 1025–1032, 2005.
- W. Pruzanski, E. Stefanski, F. C. De Beer, M. C. De Beer, A. Ravandi, and A. Kuksis, “Comparative analysis of lipid composition of normal and acute-phase high density lipoproteins,” Journal of Lipid Research, vol. 41, no. 7, pp. 1035–1047, 2000.
- A. D. Watson, M. Navab, S. Y. Hama et al., “Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein,” Journal of Clinical Investigation, vol. 95, no. 2, pp. 774–782, 1995.
- A. D. Watson, J. A. Berliner, S. Y. Hama et al., “Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein,” Journal of Clinical Investigation, vol. 96, no. 6, pp. 2882–2891, 1995.
- A. D. Watson, N. Leitinger, M. Navab et al., “Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo,” Journal of Biological Chemistry, vol. 272, no. 21, pp. 13597–13607, 1997.
- M. Navab, G. M. Ananthramaiah, S. T. Reddy et al., “The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL,” Journal of Lipid Research, vol. 45, no. 6, pp. 993–1007, 2004.
- C. L. Banka, T. Yuan, M. C. De Beer, M. Kindy, L. K. Curtiss, and F. C. De Beer, “Serum amyloid A (SAA): influence on HDL-mediated cellular cholesterol efflux,” Journal of Lipid Research, vol. 36, no. 5, pp. 1058–1065, 1995.
- A. Artl, G. Marsche, S. Lestavel, W. Sattler, and E. Malle, “Role of serum amyloid A during metabolism of acute-phase HDL by macrophages,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 20, no. 3, pp. 763–772, 2000.
- M. P. Reilly, F. C. McGillicuddy, M. L. De La Moya et al., “Inflammation impairs reverse cholesterol transport in vivo,” Circulation, vol. 119, no. 8, pp. 1135–1145, 2009.
- B. J. Van Lenten, M. Navab, D. Shih, A. M. Fogelman, and A. J. Lusis, “The role of high-density lipoproteins in oxidation and inflammation,” Trends in Cardiovascular Medicine, vol. 11, no. 3-4, pp. 155–161, 2001.
- J. P. Corsetti, D. Ryan, D. L. Rainwater, A. J. Moss, W. Zareba, and C. E. Sparks, “Cholesteryl ester transfer protein polymorphism (TaqIB) associates with risk in postinfarction patients with high C-reactive protein and high-density lipoprotein cholesterol levels,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, p. 1657, 2010.
- J. P. Corsetti, D. Ryan, A. J. Moss, W. Zareba, and C. E. Sparks, “NAD(P)H oxidase polymorphism (C242T) and high HDL cholesterol associate with recurrent coronary events in postinfarction patients,” Atherosclerosis, vol. 196, no. 1, pp. 461–468, 2008.
- J. P. Corsetti, R. T. Gansevoort, C. E. Sparks, and R. P. F. Dullaart, “Inflammation reduces HDL protection against primary cardiac risk,” European Journal of Clinical Investigation, vol. 40, no. 6, pp. 483–489, 2010.
- P. Rein, C. H. Saely, S. Beer, A. Vonbank, and H. Drexel, “Roles of the metabolic syndrome, HDL cholesterol, and coronary atherosclerosis in subclinical inflammation,” Diabetes Care, vol. 33, no. 8, pp. 1853–1855, 2010.
- P. J. Barter, M. Caulfield, and M. Eriksson, “Brewer B for the ILLUMINATE Investigators: effects of torcetapib in patients at high risk for coronary events,” New England Journal of Medicine, vol. 357, pp. 2109–2122, 2007.
- R. Movva and D. J. Rader, “Laboratory assessment of HDL heterogeneity and function,” Clinical Chemistry, vol. 54, no. 5, pp. 788–800, 2008.